Table 1

Demographics of survey respondents

N (%)
n685
Gender
 Female394 (57.5)
 Gender neutral2 (0.3)
 Male288 (42.0)
Age
 16–24 years52 (7.6)
 25–34 years104 (15.2)
 35–44 years154 (22.5)
 45–54 years139 (20.3)
 55–64 years118 (17.2)
 65–74 years76 (11.1)
 75+ years42 (6.1)
Ethnicity
 White656 (95.8)
 Asian or Asian British123 (1.9)
 Black or Black British1 (0.1)
 Mixed5 (0.7)
 Other2 (0.3)
 Prefer not to say8 (1.2)
Diagnosis
 Crohn’s disease443 (64.7)
 Ulcerative colitis211 (30.8)
 IBDU31 (4.5)
Time since IBD diagnosis
 0–2 years61 (8.9)
 3–5 years137 (20.0)
 6–10 years156 (22.8)
 11–20 years195 (28.5)
 21+ years134 (19.6)
Pre-COVID-19 medication
 Topical mesalazine21 (3.1)
 Topical steroids6 (0.9)
 Oral mesalazine146 (21.3)
 Oral budesonide12 (1.8)
 Oral prednisolone29 (4.2)
 Sulfasalazine8 (1.2)
 Immunomodulator294 (43.1)
 Anti-TNF192 (28.0)
 Ustekinumab64 (9.3)
 Vedolizumab50 (7.3)
 Tofacitinib5 (0.7)
Significant comorbidity245 (35.8)
  • IBD, inflammatory bowel disease; IBDU, inflammatory bowel disease undifferentiated; TNF, tumour necrosis factor.